Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer
Open Access
- 31 July 2020
- journal article
- review article
- Published by MDPI AG in Metabolites
- Vol. 10 (8) , 314
Abstract
Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in high-throughput technologies have, in recent times, shown promise for biomarker discovery based on genomic, transcriptomic, proteomic and metabolomic platforms. Metabolomics, the large-scale study of metabolites, deals with the downstream products of the other omics technologies and thus best reflects the human phenotype. This review aims to provide a summary and critical synthesis of the existing literature with the ultimate goal of identifying the most promising metabolite biomarkers that can augment current endometrial cancer diagnostic, prognostic and recurrence surveillance strategies. Identified metabolites and their biochemical pathways are discussed in the context of what we know about endometrial carcinogenesis and their potential clinical utility is evaluated. Finally, we underscore the challenges inherent in metabolomic biomarker discovery and validation and provide fresh perspectives and directions for future endometrial cancer biomarker research.Keywords
Funding Information
- Cancer Research UK (C147/A25254)
- National Institute for Health and Care Research (IS-BRC-1215-20007)
- Medical Research Council (MR/M008959/1)
This publication has 116 references indexed in Scilit:
- The Complex Role of Branched Chain Amino Acids in Diabetes and CancerMetabolites, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor modelsJournal of Lipid Research, 2013
- Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancerBritish Journal of Cancer, 2011
- Effects of Lysophospholipids on Tumor MicroenvironmentCancer Microenvironment, 2011
- Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tractProteome Science, 2010
- What are biomarkers?Current Opinion in HIV and AIDS, 2010
- Serum Biomarkers for Early Detection of Gynecologic CancersCancers, 2010
- Altered sphingolipid metabolism in human endometrial cancerProstaglandins & Other Lipid Mediators, 2010
- Case--Control Study of Endogenous Steroid Hormones and Endometrial CancerJNCI: Journal of the National Cancer Institute, 1996